Insmed Incorporated is a biopharmaceutical company that develops and distributes treatments for serious and rare diseases, including ARIKAYCE for Mycobacterium avium complex lung disease. Additionally, it is developing Brensocatib, an oral reversible inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder for pulmonary hypertension and other rare disorders. The company was founded in 1988 and is based in Bridgewater, New Jersey.